Top Medical News
Tumour stage and anatomic site significantly affect the prognosis of mucosal melanomas, while patient demographics and tumour thickness do not, a recent study has found.
2 days ago
Prostate radiotherapy is a viable treatment option for men with metastatic hormone-sensitive prostate cancer (mHSPC) with low metastatic burden, reports a recent meta-analysis.
Pank Jit Sin, 3 days ago
The anti-programmed death-ligand 1 (PD-L1) molecule durvalumab is now available in the treatment of lung cancer. The human monoclonal antibody durvalumab (IMFINZI®, AstraZeneca) is indicated in the treatment of unresectable stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

4 days ago
Social support and being part of social groups can improve psychological wellbeing among brain tumour patients, a new study has found.
6 days ago
In patients with newly diagnosed colorectal cancer (CRC), the incremental diagnostic yield for Lynch syndrome markedly drops after age 70 to 75 years, a recent study has shown. It thus seems reasonable to cease reflex CRC screening for LS after age 80 years due to very low efficiency, specifically in resource-limited settings.
6 days ago
Electrocardiogram (ECG) monitoring is performed less than what is considered acceptable or ideal in the management of cancer patients prescribed drugs associated with an increased risk of QT interval prolongation, a study from Canada has found.
6 days ago
Atezolizumab is a safe and effective treatment option in patients with urinary tract carcinoma, according to a recent study.
Special Reports
30 Jan 2019
In March 2018, sublingual fentanyl citrate (SLF; Abstral®, Menarini) was made available in Malaysia. SLF is a rapid-onset opioid (ROO) indicated for the management of breakthrough cancer pain (BTcP) episodes in patients that are opioid-tolerant. In July 2018, Menarini organized an expert meeting, aptly named Malaysian Collaborative Meeting of Pain Specialists to Improve Oncology Management (MY-COMPASSION), comprising of key figures in anaesthesiology, palliative care and oncology to discuss current insights into local BTcP management. Below are highlights from the meeting.
Dr. Jeffrey Ross, Dr. Rohit Lal, Prof. Alwin Krämer, Dr. Rebecca Dent, Prof. Rafal Dziadziuszko, 24 Jan 2019
Comprehensive genomic profiling (CGP) has emerged as a key driving force behind personalized cancer care. With the wealth of data available with CGP, medical oncologists now have in their armamentarium a tool that could enable them to provide patients with the optimum treatment. At a Roche Foundation Medicine-sponsored symposium held at the 2018 European Society of Medical Oncology (ESMO) Congress in Munich, Germany, a panel of experts reviewed key data on CGP, with a focus on the treatment of advanced cancers.
21 Nov 2018
Recently, a Roche-sponsored dinner symposium was held in conjunction with the launch of atezolizumab (Tecentriq®, Roche) at Royale Chulan, Kuala Lumpur. Important insights into the evolving treatment landscape of anticancer treatment, and the increasingly prominent role of immunotherapy were gathered from a distinguished panel, including Dato’ Dr Mohamed Ibrahim, Professor Dr Rolf A. Stahel, Dr Voon Pei Jye, and Associate Professor Dr Tho Lye Mun. Here are the highlights of the meeting.
19 Sep 2018
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
24 Jul 2018
At a recent dinner symposium held during the Abstral® Grand Launch at Le Meridien Putrajaya, Dr Michael Überall spoke on the management of breakthrough cancer pain (BTcP) and highlighted the role of sublingual fentanyl ([SLF], Abstral®; A. Menarini Pte Ltd) in the optimization of BTcP in cancer patients.
21 May 2018
At the recent American Society of Haematology Annual Meeting 2017, Professor François-Xavier Mahon reviewed recent studies related to tyrosine kinase inhibitor (TKI) cessation in patients with chronic myeloid leukaemia (CML) who have achieved sustained deep molecular response (DMR).
01 May 2018
ABSTRAL - Fentanyl citrate 100 mcg, 200 mcg and 400 mcg SL tab - A. Menarini
Conference Reports
Elaine Soliven, 18 Jun 2019
Neoadjuvant treatment with trastuzumab emtansine (T-DM1) plus pertuzumab led to a higher risk of 3-year event-free survival (EFS) events in patients with HER2-positive breast cancer, according to a secondary analysis of the KRISTINE* trial presented at ASCO 2019.
Christina Lau, 18 Jun 2019

Patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) may have their overall survival (OS) and progression-free survival (PFS) approximately doubled with pembrolizumab in combination with platinum-based chemotherapy vs chemotherapy alone, according to updated results of the KEYNOTE-189 trial reported at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
17 Jun 2019
Slideshow: Highlights from the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
Roshini Claire Anthony, 16 Jun 2019

The addition of the CDK* 4/6 inhibitor ribociclib to endocrine therapy significantly extended overall survival (OS) in premenopausal women with HR+ HER2- advanced breast cancer, as evidenced in the phase III MONALEESA-7** trial.

Pearl Toh, 15 Jun 2019
Adding apalutamide to androgen-deprivation therapy (ADT) significantly extends radiographic progression-free survival (rPFS) and overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared with ADT alone, the TITAN* study shows.
Audrey Abella, 14 Jun 2019
The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.
Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download